Noam Savion Gaiger
Hospital ResidentAbout
Research
Publications
2026
Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab
Savion-Gaiger N, Perales O, Su D, Bar-Ziv D, Challa P, Djureinovic D, Yi I, Adeniran A, Kluger H, Schoenfeld D. Compartment-specific immune and tumor markers associated with clinical outcomes in patients with and without sarcomatoid/rhabdoid renal cell carcinoma treated with ipilimumab and nivolumab. ESMO Open 2026, 11: 106908. PMID: 42013628, PMCID: PMC13123346, DOI: 10.1016/j.esmoop.2026.106908.Peer-Reviewed Original ResearchThis study investigates biomarkers in renal cell carcinoma, showing tumor PD-L1 expression predicts better survival with immunotherapy, while neutrophil markers highlight sarcomatoid/rhabdoid tumor immune environments.
2025
Survival of patients with metastatic renal cell carcinoma with or without brain metastases
Savion-Gaiger N, Considine B, Hasson N, Nelson M, Chiang V, Kluger H, Braun D, Schoenfeld D, Sznol M, Leapman M, Hurwitz M. Survival of patients with metastatic renal cell carcinoma with or without brain metastases. The Oncologist 2025, 30: oyaf387. PMID: 41287461, PMCID: PMC12704413, DOI: 10.1093/oncolo/oyaf387.Peer-Reviewed Original ResearchImmune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients
Gaiger N, Hurwitz M, Hafez N, Kluger H, Herold K, Perdigoto A. Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients. Frontiers In Endocrinology 2025, 16: 1697724. PMID: 41282287, PMCID: PMC12634352, DOI: 10.3389/fendo.2025.1697724.Peer-Reviewed Original ResearchFactors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes
Aizenbud L, Gaiger N, Perdigoto A, Mann J, Torres M, Boland G, Lawless A, Silverman S, Schoenfeld D, Destina J, Hasson N, Tran T, Hurwitz M, Austin M, Sullivan R, Herold K, Kluger H. Factors that increase class I MHC expression may contribute to the development of immune checkpoint inhibitor-induced diabetes. Journal For ImmunoTherapy Of Cancer 2025, 13: e012358. PMID: 40935567, PMCID: PMC13059913, DOI: 10.1136/jitc-2025-012358.Peer-Reviewed Original ResearchMicroglial reprogramming: a potential new frontier in enhancing immunotherapy for melanoma brain metastasis
Savion‐Gaiger N, Bar‐Ziv D, Kluger H. Microglial reprogramming: a potential new frontier in enhancing immunotherapy for melanoma brain metastasis. Molecular Oncology 2025, 19: 1291-1294. PMID: 40111148, PMCID: PMC12077281, DOI: 10.1002/1878-0261.70028.Peer-Reviewed Original Research
2024
Artificial Intelligence in Healthcare: A New Frontier in Predicting and Managing Chronic Diseases.
Nathan N, Saring M, Savion-Gaiger N, Radinsky K, Peri A. Artificial Intelligence in Healthcare: A New Frontier in Predicting and Managing Chronic Diseases. Israel Medical Association Journal 2024, 26: 108-113. PMID: 38420983.Peer-Reviewed Original Research
2023
The effect of body mass index reduction on intraocular pressure in a large prospective cohort of apparently healthy individuals in Israel
Coster D, Rafie A, Savion-Gaiger N, Rachmiel R, Kurtz S, Berliner S, Shapira I, Zeltser D, Rogowski O, Shenhar-Tsarfaty S, Waisbourd M. The effect of body mass index reduction on intraocular pressure in a large prospective cohort of apparently healthy individuals in Israel. PLOS ONE 2023, 18: e0285759. PMID: 37196013, PMCID: PMC10191308, DOI: 10.1371/journal.pone.0285759.Peer-Reviewed Original Research
News
Get In Touch
Contacts
Mobile Phone Number